{{Rsnum
|rsid=1131454
|Gene=OAS1
|Chromosome=12
|position=112911065
|Orientation=plus
|GMAF=0.4867
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=OAS1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 30.1 | 53.1 | 16.8
| HCB | 32.1 | 44.5 | 23.4
| JPT | 42.5 | 48.7 | 8.8
| YRI | 1.4 | 18.8 | 79.9
| ASW | 10.5 | 38.6 | 50.9
| CHB | 32.1 | 44.5 | 23.4
| CHD | 33.9 | 50.5 | 15.6
| GIH | 28.7 | 49.5 | 21.8
| LWK | 2.7 | 17.3 | 80.0
| MEX | 44.8 | 41.4 | 13.8
| MKK | 1.3 | 28.4 | 70.3
| TSI | 17.6 | 53.9 | 28.4
| HapMapRevision=28
}}

{{omim
|id=164350
|rsnum=1131454
|variant=0002
}}

{{PMID Auto
|PMID=21638280
|Title=2'-5' oligoadenylate synthetase 1 polymorphism is associated with prostate cancer
|OA=1
}}

{{ClinVar
|rsid=1131454
|Reversed=0
|FwdREF=G
|FwdALT=A,C
|REF=G
|ALT=A,C
|RSPOS=113348870
|CHROM=12
|GMAF=0.4872
|dbSNPBuildID=86
|SSR=0
|SAO=1
|VP=0x05036800000017051f110100
|GENEINFO=OAS1:4938
|GENE_NAME=OAS1
|GENE_ID=4938
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000012.11:g.113348870G>A
|CLNORIGIN=1
|CLNSIG=255
|Tags=PM;PMC;S3D;SLO;VLD;G5A;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.5133; 0.4867; .
|CLNACC=RCV000015022.1
|CLNDBN=Diabetes mellitus, type 1, susceptibility to
|CLNSRC=OMIM Allelic Variant
|CLNSRCID=164350.0002
|COMMON=1
|Disease=Diabetes mellitus
}}

{{PMID Auto
|PMID=15732009
|Title=Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene.
|OA=1
}}

{{PMID Auto
|PMID=19247438
|Title=Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man.
|OA=1
}}

{{PMID Auto
|PMID=19434718
|Title=Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|OA=1
}}

{{PMID Auto
|PMID=19956101
|Title=Overview of the Rapid Response data.
|OA=1
}}

{{PMID Auto
|PMID=19956105
|Title=Reassessment of the type I diabetes association of the OAS1 locus.
|OA=1
}}

{{PMID Auto
|PMID=20079393
|Title=2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.
|OA=1
}}

{{GET Evidence
|gene=OAS1
|aa_change=Gly162Ser
|aa_change_short=G162S
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1131454
|overall_frequency_n=4858
|overall_frequency_d=10758
|overall_frequency=0.451571
|n_genomes=38
|n_genomes_annotated=0
|n_haplomes=49
|n_articles=0
|n_articles_annotated=0
|nblosum100=2
|autoscore=0
|webscore=N
}}

{{PMID Auto
|PMID=22710942
|Title=Evaluate the relationship between polymorphisms of OAS1 gene and susceptibility to chronic hepatitis C with high resolution melting analysis.
}}

{{PMID Auto
|PMID=23337612
|Title=Polymorphisms in the oligoadenylate synthetase gene cluster and its association with clinical outcomes of dengue virus infection.
}}

{{PMID Auto
|PMID=25205466
|Title=Mitochondrial localization of the OAS1 p46 isoform associated with a common single nucleotide polymorphism
}}
{{on chip | 23andMe v3}}